4TEEN4 Pharmaceuticals has expanded its Series C financing round to €55 million, securing participation from both existing and new investors to accelerate the development of its lead monoclonal antibody therapy, procizumab, for patients suffering from cardiogenic shock. The company will use the additional capital to support further its ongoing multicenter Phase 2a PROCARD 2a clinical trial, broaden the study footprint across Europe, and prepare for planned expansion into the United States.
The funding strengthens 4TEEN4’s ability to advance the evaluation of procizumab, which is designed to neutralize circulating dipeptidyl peptidase 3, a pathological driver of acute cardiovascular collapse. Shock is a severe condition resulting from rapid circulatory failure that frequently progresses to multi-organ dysfunction and is associated with more than fifty percent mortality. Cardiogenic shock, most commonly caused by acute myocardial infarction or acute decompensated heart failure, remains a significant unmet need due to the absence of approved therapies that address the underlying biological mechanisms.
The Phase 2a study is assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of procizumab in patients with cardiogenic shock characterized by elevated levels of cDPP3. 4TEEN4 dosed its first patient in July 2025 and anticipates initial interim safety and PK/PD data in early 2026. The company emphasized that the newly added capital will support continued enrollment and operational readiness ahead of a pivotal late-stage trial.
Procizumab has demonstrated the ability to restore cardiovascular stability by inhibiting CDPP3 activity, thereby helping to rebalance the renin-angiotensin-aldosterone system that becomes dysregulated when CDPP3 is released into circulation following cellular injury. Preclinical and early clinical data have shown improvements in cardiovascular parameters, reversal of organ dysfunction, enhanced survival, and a favorable safety profile, as demonstrated in a completed Phase 1 study involving healthy volunteers.
Investors in this extended round include prior institutional backers, as well as new institutional funds, family offices, and private investors.
4TEEN4 reiterated its mission to develop a first-in-class targeted therapy that moves shock treatment beyond supportive measures and addresses the biological cause of mortality in critically ill patients.
KEY QUOTES
“This financing reflects a strong vote of confidence in 4TEEN4’s mission and the transformative potential of our science to improve survival in critically ill patients. This investment enables us to advance our PROCARD 2a study, creating a comprehensive framework for our planned pivotal study for procizumab. Together with our investors, we are progressing toward delivering a breakthrough therapy that moves beyond supportive care for patients with life-threatening shock.”
Dr. Andreas Bergmann, CEO of 4TEEN4 Pharmaceuticals
“The proceeds from our Series C strengthen our financial position and will be used to reach key clinical milestones for procizumab, including the interim safety, pharmacokinetic, and pharmacodynamic analysis expected in early 2026, as well as subsequent PROCARD 2a readouts. This capital enables us to further de-risk our lead candidate and accelerate progress toward data that could transform care for patients in urgent need of treatment options, while creating sustainable long-term value for our shareholders.”
Dr. Kilian von Seldeneck, CFO of 4TEEN4 Pharmaceuticals
